Statement: Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial.
Primary_evidence: Inclusion:   Histologically confirmed breast cancer   Clinically or radiographically measurable residual tumor after core biopsy   Eastern Cooperative Oncology Group (ECOG) performance status 0-1   Age 18 yrs   Absolute neutrophil count  1,500/mm³   Hemoglobin  9 g/dL   Platelet count  100,000/ mm³   Creatinine  1.5 times upper limit of normal (ULN)   Urine protein:creatinine ratio < 1.0   AST (aspartate aminotransferase) and ALT  2.5 times ULN   Alkaline phosphatase  2.5 times ULN   Bilirubin normal   Women of childbearing potential must use effective contraception   Left ventricular ejection fraction (LVEF) normal by echocardiogram or MUGA   Exclusion:   No residual tumor after initial biopsy   Peripheral neuropathy of grade 2 or higher   HER-2 neu overexpression either by IHC 3+ or FISH+   No history of any prior treatment of breast cancer.   No history of unstable angina or myocardial infarction within the past 12 months   Pregnant or nursing women   Anticoagulation therapy within the last 6 months   History of gastrointestinal bleeding   Recent hemoptysis   No known hepatitis B or HIV seropositivity   No inadequately controlled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg and/or diastolic BP > 100 mm Hg despite antihypertensive medications   History of hypertensive crisis or hypertensive encephalopathy   New York Heart Association class II-IV congestive heart failure   History of stroke or transient ischemic attack at any time   Significant vascular disease (e.g., aortic aneurysm or aortic dissection)   No symptomatic peripheral vascular disease   Evidence of bleeding diathesis or coagulopathy   Significant traumatic injury within the past 28 days   History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months   Serious, non-healing wound, ulcer, or bone fracture   Known hypersensitivity to any component of bevacizumab
Secondary_evidence: Inclusion Criteria:   Woman, 18 years old or upper.   Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are:   immuno-histochemistry (IHC) 3+ (>10% of tumor cells with complete and intense membrane staining)   IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (*)   FISH / CISH / SISH + for HER 2 amplification (*) (*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)> 2.2, or a number of copies of HER 2/neu> 6, as per local laboratory criteria.   Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.   No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a life expectancy of at least 3 months.   Adequate performance status: Eastern Cooperative Oncology Group (ECOG) <2.   Adequate bone marrow function, liver and kidney   Proper cardiac function (LVEF within normal limits the center, measured by echocardiography or MUGA).   The patient must have been informed of the study and must sign and date informed consent document for entry into the trial.   The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires. Exclusion Criteria:   Patients with no advanced breast cancer.   Breast cancer patients with tumors HER 2-negative.   The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear> 5 years without evidence of disease could be included.   The patient has uncontrolled brain metastases.   Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.   Known hypersensitivity to trastuzumab or to any of its components.   Patients with severe dyspnea at rest or requiring supplemental oxygen.   Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.   Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).   The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.